Natural gas: Shipping channel drives gas volatility – Societe Generale
Societe Generale analysts Michael Haigh and Jeremy Sellem argue that LNG shipping conditions are central to how maritime risk transmits into natural gas volatility. As Europe relies more on LNG imports and the United States on exports, freight costs, inventory adequacy and security of LNG trade routes become key drivers of implied volatility, especially during periods of heightened maritime disruptions.
Freight and inventories shape LNG risk
"Natural gas markets rely heavily on LNG shipping routes and inventory adequacy, making them particularly sensitive to disruptions affecting maritime logistics and energy security."
"The stronger relationship observed in gas markets is unlikely to be coincidental. Unlike refined products, natural gas increasingly relies on global LNG trade and maritime transportation. As Europe became more dependent on LNG imports and the United States emerged as the dominant source of export growth, shipping conditions have become a more important component of gas-market dynamics."
"LNG freight costs and TTF realized volatility surged simultaneously during the most acute phase of the 2026 maritime-risk shock. While freight rates measure the cost of transporting LNG cargoes rather than the price of gas itself, the observed co-movement highlights a potential transmission channel linking maritime disruptions to European gas-market volatility."
"Lastly, we assess the sensitivity to maritime attacks under different inventory levels. Not surprisingly, when inventory levels are tight, the impact on volatility is much greater. As European inventory levels are considerably lower than seasonal norms, we would expect with more attacks during the heating season, for implied volatility to increase."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
